KR20190112046A - 이명 치료에 가복사돌의 사용 - Google Patents

이명 치료에 가복사돌의 사용 Download PDF

Info

Publication number
KR20190112046A
KR20190112046A KR1020197024876A KR20197024876A KR20190112046A KR 20190112046 A KR20190112046 A KR 20190112046A KR 1020197024876 A KR1020197024876 A KR 1020197024876A KR 20197024876 A KR20197024876 A KR 20197024876A KR 20190112046 A KR20190112046 A KR 20190112046A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acceptable salt
patient
hours
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020197024876A
Other languages
English (en)
Korean (ko)
Inventor
매튜 듀링
Original Assignee
오비드 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오비드 테라퓨틱스 인크. filed Critical 오비드 테라퓨틱스 인크.
Publication of KR20190112046A publication Critical patent/KR20190112046A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197024876A 2017-02-03 2018-02-02 이명 치료에 가복사돌의 사용 Abandoned KR20190112046A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762454280P 2017-02-03 2017-02-03
US62/454,280 2017-02-03
US201762530528P 2017-07-10 2017-07-10
US62/530,528 2017-07-10
US201762536669P 2017-07-25 2017-07-25
US62/536,669 2017-07-25
PCT/US2018/016602 WO2018144827A1 (en) 2017-02-03 2018-02-02 Use of gaboxadol in the treatment of tinnitus

Publications (1)

Publication Number Publication Date
KR20190112046A true KR20190112046A (ko) 2019-10-02

Family

ID=63038963

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197024876A Abandoned KR20190112046A (ko) 2017-02-03 2018-02-02 이명 치료에 가복사돌의 사용

Country Status (17)

Country Link
US (3) US10071083B2 (https=)
EP (1) EP3576738B1 (https=)
JP (3) JP2020505432A (https=)
KR (1) KR20190112046A (https=)
CN (1) CN110402140A (https=)
AU (1) AU2018215363A1 (https=)
BR (1) BR112019015832A2 (https=)
CA (1) CA3051586A1 (https=)
DK (1) DK3576738T3 (https=)
ES (1) ES2930899T3 (https=)
HU (1) HUE060609T2 (https=)
IL (1) IL268210A (https=)
MX (1) MX393900B (https=)
PE (1) PE20191407A1 (https=)
PL (1) PL3576738T3 (https=)
PT (1) PT3576738T (https=)
WO (1) WO2018144827A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4541420A3 (en) 2015-07-17 2025-06-25 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
EP3481387A4 (en) 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
WO2020061410A1 (en) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
JP2022514194A (ja) 2018-11-21 2022-02-10 セルテゴ セラピューティクス インコーポレイテッド 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
WO2020131856A1 (en) * 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
US11364228B2 (en) 2019-12-18 2022-06-21 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
EP4299059A1 (en) 2022-07-01 2024-01-03 Labelic Analysis, S.L. Composition for the treatment of tinnitus

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US3947579A (en) 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
US4138484A (en) 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20070032553A1 (en) * 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
JP2007530604A (ja) 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
DE102005004343A1 (de) 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
US20080262029A1 (en) * 2005-04-29 2008-10-23 H. Lundbeck A/S Acid and Base Salt Forms of Gaboxadol
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
PL2083811T3 (pl) 2006-11-22 2017-05-31 Clinical Research Associates, Llc Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu
AU2007346591A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
DE102007063210A1 (de) 2007-12-20 2009-06-25 Eberhard-Karls-Universität Tübingen Universitätsklinikum Arzneimittel zur Behandlung von Phantomphänomenen
JP2011507800A (ja) * 2007-12-26 2011-03-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 癲癇、精神障害、または感覚器官の障害のためのａｍｐａ受容体アンタゴニスト
DK2621282T3 (da) 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
WO2012075286A2 (en) 2010-12-01 2012-06-07 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
US20140371210A1 (en) 2011-10-13 2014-12-18 Jaleva Pharmaceuticals, Llc Methods and compositions for rapid transbuccal delivery of active agents
AU2013352141B2 (en) 2012-11-30 2018-04-05 The Regents Of The University Of California Anticonvulsant activity of steroids
WO2014123909A1 (en) 2013-02-05 2014-08-14 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
RS62007B1 (sr) 2014-06-06 2021-07-30 Ovid Therapeutics Inc Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma
CA2951497C (en) 2014-06-12 2019-04-09 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
EP4541420A3 (en) 2015-07-17 2025-06-25 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
JP6857647B2 (ja) 2015-08-11 2021-04-14 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． クリティカル・ケア処置中に用いるための鎮静方法および非経腸製剤
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
EP3481387A4 (en) 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
JP2022514194A (ja) * 2018-11-21 2022-02-10 セルテゴ セラピューティクス インコーポレイテッド 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール

Also Published As

Publication number Publication date
MX2019009190A (es) 2019-09-26
CA3051586A1 (en) 2018-08-09
IL268210A (en) 2019-09-26
PT3576738T (pt) 2022-11-30
AU2018215363A1 (en) 2019-08-15
JP2024178317A (ja) 2024-12-24
WO2018144827A1 (en) 2018-08-09
EP3576738A4 (en) 2021-02-17
PE20191407A1 (es) 2019-10-04
US10071083B2 (en) 2018-09-11
JP2023011630A (ja) 2023-01-24
US20190111033A1 (en) 2019-04-18
CN110402140A (zh) 2019-11-01
BR112019015832A2 (pt) 2020-03-31
US20180344709A1 (en) 2018-12-06
EP3576738B1 (en) 2022-10-12
EP3576738A1 (en) 2019-12-11
JP2020505432A (ja) 2020-02-20
ES2930899T3 (es) 2022-12-22
US10188635B2 (en) 2019-01-29
DK3576738T3 (da) 2022-11-28
PL3576738T3 (pl) 2023-02-06
MX393900B (es) 2025-03-24
US20180221355A1 (en) 2018-08-09
HUE060609T2 (hu) 2023-04-28

Similar Documents

Publication Publication Date Title
US10071083B2 (en) Use of gaboxadol in the treatment of tinnitus
Pallanti et al. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial
Young et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo-and haloperidol-controlled study
Kupfer Pathophysiology and management of insomnia during depression
AU2016295138B2 (en) Methods of treating developmental disorders with gaboxadol
AU2019216742B2 (en) Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
Oertel et al. Late (complicated) Parkinson’s disease
US11744833B2 (en) Pharmaceutical compositions and methods for treatment of insomnia
EP4478887A1 (en) Novel pharmaceutical compositions and methods for treatment of insomnia
HK40015478A (en) Use of gaboxadol in the treatment of tinnitus
Marino et al. Review of pharmacologic sleep agents for critically ill patients
US11771671B2 (en) Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
Fagiolini et al. Intramuscular aripiprazole for the treatment of agitation in schizophrenia and bipolar disorder: From clinical research to clinical practice [Aripiprazolo intramuscolare per il trattamento dell’agitazione nella schizofrenia e nel disturbo bipolare: dalla ricerca alla pratica clinica]
Cyrus Review of Pharmacologic Sleep Agents for Critically III
Kushida Pharmacologic Treatment of Insomnia
Rajiv et al. First-line Therapy in Status Epilepticus
Lee-Chiong et al. Pharmacologic Therapy of Chronic Insomnia in Older Adults
Spiller et al. Aripiprazole monotherapy in acute mania: 12-week randomised
EP2255807A1 (en) Method of treating sleep disorders using the combination of eplivanserin and zolpidem

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PC1904 Unpaid initial registration fee

St.27 status event code: A-2-2-U10-U14-oth-PC1904

St.27 status event code: N-2-6-B10-B12-nap-PC1904

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000